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Severe acute respiratory infections, including influenza, are a leading cause of cardiopulmonary morbidity and
mortality worldwide. Until recently, the epidemiology of influenza was limited to resource-rich countries.
Emerging epidemiological reports characterizing the 2009 H1N1 pandemic, however, suggest that influenza
exerts an even greater toll in low-income, resource-constrained environments where it is the cause of 5% to
27% of all severe acute respiratory infections. The increased burden of disease in this setting is multifactorial
and likely is the result of higher rates of comorbidities such as human immunodeficiency virus, decreased
access to health care, including vaccinations and antiviral medications, and limited healthcare infrastructure,
including oxygen therapy or critical care support. Improved global epidemiology of influenza is desperately
needed to guide allocation of life-saving resources, including vaccines, antiviral medications, and direct the
improvement of basic health care tomitigate the impact of influenza infection on themost vulnerable populations.(HL10871203, HL12299801,
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j.gheart.2014.08.004Severe acute respiratory infections (SARI) including
influenza represent a leading cause of global morbidity and
mortality. Each year, an estimated 5% to 10% of adults and
20% to 30%of children are infected with influenza, resulting
in 3 to 5 million cases of severe disease and approximately 1
million deaths worldwide [1]. Until recently, the epidemi-
ology of influenza has been primarily derived from resource-
rich settings. Emerging data from the 2009 H1N1 pandemic,
however, suggests that influenza exerts an even greater toll on
patients in resource-limited environments due to decreased
access to health care, limited healthcare infrastructure, and
shortages of healthcare personnel. This includes poor avail-
ability of vaccinations and critical care support, and the high
prevalence of comorbidities such as human immunodefi-
ciency virus (HIV) infection and malnutrition.
Influenza is a respiratory virus that, despite the avail-
ability of vaccines and effective antiviral medications, exerts
a substantial toll on global morbidity and mortality every
year. Seasonal influenza is often clinically mild, recognized
by a constellation of symptoms including fever and cough
or sore throat, which is classified as “influenza-like illness”
(ILI) in the absence of a known cause other than influenza
[2]. More severe influenza infections can occur and are
further classified as SARI if the patient with ILI has
shortness of breath [3]. Pandemics occur when a novel
influenza virus enters into the human population and is
capable of spreading rapidly. The most severe pandemic
occurred in 1918 when an influenza virus crossed over
from birds to humans and killed an estimated 50 to 100
million people with a mortality rate of approximately 2% to
2.5% [4]. Recently, a number of influenza viruses (H5N1
and H7N9) have emerged with pandemic potential and
even greater mortality rates of up to 60%, but they have not
yet reached sustained transmission in humans [5,6]. In AprilGLOBAL HEART, VOL. 9, NO. 3, 2014
September 2014: 325-3362009, a novel strain of H1N1 influenza jumped from swine
into humans and infected over 200 million people globally,
resulting in the first influenza pandemic of the 21st century.
Despite a wealth of information about influenza from
resource-rich countries, very little is known about influenza’s
epidemiology and sequelae in resource-limited countries.
Given the global impact of influenza and the paucity of
data for many countries, this review represents an initial step
to better characterize the burden of influenza including
epidemiology, sequelae of severe influenza infection, and
strategies to improve supportive care and virus-specific
therapy in resource-limited, low-income settings. The re-
view will examine the available epidemiology in resource-
limited countries with a specific focus on the first year of
the 2009 H1N1 pandemic as well the known risk factors for
influenza in these settings. The most prominent sequelae of
infection including cardiopulmonary complications will
then be reviewed. Finally, it will consider treatment and
remaining barriers to improving influenza care globally.SENTINEL SURVEILLANCE OF 2009 PANDEMIC
H1N1 INFLUENZA IN LOW- AND LOW-MIDDLE-
INCOME COUNTRIES
Since the outbreak of avian H5N1 influenza in 1997, there
has been growing recognition of the need for improved global
surveillance of influenza. In response, the World Health
Organization (WHO) launched the Global Agenda for
Influenza Surveillance and Control in 2001, which priori-
tized influenza surveillance as part of a comprehensive
strategy to reduce morbidity and mortality from annual
influenza epidemics [7]. Despite the implementation of basic
influenza surveillance systems across the globe, very little was
reported about seasonal influenza in resource-limited areas.325
j gREVIEW
326The global spread of pandemic H1N1 in 2009 repre-
sented the first influenza pandemic of the 21st century.
Within a year, cases were reported in more than 214 coun-
tries, overseas territories, and communities [8]. On June 11,
2009, WHO raised the pandemic alert to a level 6, the
highest level, indicating evidence of sustained human-to-
human transmission and global spread of this virus. In the
United States alone, there were an estimated 59 million ill-
nesses, 265,000 hospitalizations, and 12,000 deaths as of
February 2010 [9]. The pandemic was declared over in
August 2010 but not before an estimated 200 million
people were infected [8]. Approximately 18,500 laboratory-
confirmed deaths due to H1N1 were reported to WHO.
However, these numbers are likely a gross under-
representation of the true burden of global influenza due
to a lack of standardized case reporting or access to health
care [10]. Early reports of highmorbidity andmortality from
Mexico, an upper-middle-income country according to the
World Bank, suggested that an excess in mortality and life
years lost occurs in more resource-limited settings [11].
Furthermore, of the 18,500 2009 pandemic H1N1 (pH1N1)
influenza deaths reported to WHO, only 168 (0.9%) were
from Africa, despite its being home to 12% of the world’s
population [12]. The juxtaposition between the large
numbers of people living in low-income countries and the
small numbers of infections and deaths due to 2009 pH1N1
influenza in these settings highlighted the gap in the current
understanding of the global burden of influenza.
To better characterize the effect of influenza infection in
resource-limited or low-income areas, we performed a
comprehensive search of articles related to the 2009 H1N1
pandemic influenza in low-income and lower-middle-income
countries using the following combined search terms: “(swine
or H1N1) and (flu or influenza or virus or outbreak or
pandemic) and (Africa or Southeast Asia or India or Eastern
Europe or resource limited or low income).” A total of 1,941
articles were identified and evaluated for content, including
primary data related to sentinel surveillance of patients with
influenza between 2009 and 2010. Of those, 1,823 studies
were excluded, as they did not contain primary data relevant
to this study. The remaining 118 were reviewed and 97 were
excluded as they did not report data from low-income
countries or included only pediatric populations. We
analyzed the subsequent 21articles to characterize the sentinel
surveillance of the 2009 H1N1 influenza pandemic in low-
income countries (Table 1) [13e23].
North Africa
Morocco. Morocco is a country of 33 million people
located in Northwest Africa [24]. In line with the WHO
Global Agenda for Influenza Surveillance and Control,
Morocco strengthened influenza sentinel surveillance in
2007. As a result, 3,102 respiratory samples were collected
between 2007 and 2009 with 98 (3%) of these samples
positive for influenza [20]. The emergence of the 2009
H1N1 pandemic led to increased surveillance resulting inthe collection of 3,937 samples between June 2009 and
February 2010 alone [15]. Of these, approximately 1,452
(37%) tested positive for 2009 pandemic H1N1 influenza.
Approximately 40% of patients who presented with ILI and
27% with SARI were positive for 2009 pH1N1 [15]. The
largest number of patients with ILI and SARI occurred in
children under 15 (56% and 51%, respectively) [15,19].
Sixty-four patients (19%) admitted with SARI died, which
highlights the poor outcome of severe influenza in Morocco.
Whereas severe disease was observed with similar frequency
in all age groups (19% in children <5 years, 33% in chil-
dren 5 to 14, 27% in those 15 to 24; 33% in those 25 to 59,
and 25% in those >60), death occurred to a greater extent
in adults between the ages of 25 and 59 years, which is
similar to that found in the United States and Europe.
Influenza in Morocco was seasonal with peak transmission
between October and April [20]. Influenza vaccination was
reported in only 2% to 4% of patients presenting with ILI or
SARI [20]. The high proportion of patients presenting with
ILI and SARI due to influenza suggests that influenza may be
a leading cause of vaccine-preventable respiratory infection
and mortality in North Africa.
West Africa
Guinea, Mali, and Niger. Despite the fact that by
December 2009, approximately 92% of countries world-
wide had reported 1 case of 2009 H1N1 influenza, 75%
of countries (12 of 16) in West Africa had yet to report a
single case [18]. In an attempt to understand the trans-
mission of 2009 pandemic H1N1 in Africa, surveillance
data was obtained from 10 countries during the 2009
pandemic [18]. Between May 4, 2009, and April 3, 2010, a
total of 10,203 respiratory samples were tested, of which
25% were positive for H1N1 pandemic influenza [18].
Between May 2009 and April 2010, 12 of 98 (12%), 53 of
422 (13%), and 90 of 388 (23%) samples were positive for
influenza in Guinea, Mali and Niger, respectively. The
2009 pandemic H1N1 virus was first detected in Cape
Verde and Cote d’Ivoire in June 2009 followed by Ghana
and Cameroon (August 2009); Mauritania, Guinea, and
Senegal (December 2009); Mali (January 2010); and finally
Niger in February 2010 [18]. Only 14% of samples tested
through the end of December 2009 were positive for the
2009 H1N1 pandemic strain, indicating that the belated
detection of cases in Mauritania, Guinea, Senegal, Mali, and
Niger truly represented a delayed spread of the 2009 H1N1
influenza virus in West Africa [18].
Nigeria. As the most populous country in Africa (173
million people), Nigeria only expanded influenza sentinel
surveillance in 2008, building on a foundation established as
part of WHO’s African Region’s Integrated Disease Surveil-
lance and Response strategy [25]. Between 2009 and 2010,
2,803 samples were obtained from patients presenting with
ILI or SARI (412 were unclassified as either ILI or SARI)
from 4 sentinel sites [16]. Of these, 217 patients (8%) testedGLOBAL HEART, VOL. 9, NO. 3, 2014
September 2014: 325-336
TABLE 1. Influenza sentinel surveillance in low- and lower-middle-income countries during the first year of the
2009 H1N1 influenza pandemic
Country (Region) Income
Population












Morocco Lower middle 33 June 2009eFebruary
2010
3,937 1,452 (37)y 1,056 (40)y 342 (27)y
West Africa
Guinea Low 12 May 2009eApril 2010 98 12 (12) NR NR
Mali Low 15 May 2009eApril 2010 422 53 (13) NR NR
Niger Low 18 May 2009eApril 2010 388 90 (23) NR NR
Nigeria Lower middle 174 April 2009eAugust 2010 2,803 217 (8) 167 (8) 17 (5)
Sub-Saharan
Africa
Rwanda Low 12 2009e2010 2,552 369 (15) 273 (25) 96 (7)




Low 66 January 2009eDecember
2009
1,311 249 (19) 208 (20) 41 (16)
Tanzania Low 49 2009e2010 1,810 154 (9) 97 (9) 57 (8)
Asia
India (South) Lower middle 1,252 May 2009eApril 2010 2,588 699 (27) 489 (35%) 210 (18%)
India (Andhra
Pradesh)
Lower middle 1,252 May 2009eDecember
2010
6,527 1,480 (23) NR NR
Bangladesh Low 157 2009e2010 2,377 391 (16) 273 (17) 118 (16)
Bhutan Lower middle <1 2009e2011 2,149 711 (33) NR NR
Lao PDR Lower middle 7 January 2008eDecember
2010
2,338* 523 (22) 523 (22) NR
Philippines Lower middle 98 January 2009eDecember
2010
5,616 1,220 (22) 1,068 (26) 152 (11)
Income classification is according to the World Bank. Low income is defined as a per capita gross national income $1,045, whereas lower-middle-
income countries are those with a per capita gross national income of >$1,045 but <$4,125 [23]. ILI, influenza-like illness; NR, not recorded; PDR,
People’s Democratic Republic; pH1N1, 2009 pandemic H1N1; SARI, severe acute respiratory infection.
*ILI only.
ypH1N1 only.
gREVIEWjpositive for influenza, of which 167 (77%) presented with
ILI and 17 (8%) with SARI [16]. In contrast to reports from
elsewhere in Africa, influenza accounted for a lower per-
centage of ILI and SARI cases in Nigeria with 8.1% and 5%,
respectively. An overwhelming majority of ILI and SARI
occurred in children under 5 (67.8 and 71.6, respectively)
concerning for reporting bias or a skewed utilization of
healthcare resources. Although individuals presenting with
ILI due to pandemic H1N1 were most commonly between
the ages of 5 and 17, SARI due to pH1N1 was most
frequently detected in individuals over the age of 65 [16].
Seasonality of influenza in Nigeria was less pronounced, but
peak influenza activity between 2009 and 2010 occurred
during November 2009 and March 2010.Sub-Saharan Africa
Influenza is often confused with other febrile illnesses in
Sub-Saharan Africa and thus the epidemiology remainsGLOBAL HEART, VOL. 9, NO. 3, 2014
September 2014: 325-336poorly defined in this area. Additionally, influenza surveil-
lance in this region has been limited due to financial con-
straints, limited public health infrastructure, and competing
health priorities such as tuberculosis, malaria, and HIV [21].
Rwanda. Rwanda, a Sub-Saharan country of almost 12
million people, initiated an influenza sentinel surveillance
program in collaboration with the US Centers for Disease
Control and Prevention in 2008 [26]. Between October
2009 and May 2010, the Rwandan National Reference
Laboratory tested 2,045 samples from patients meeting the
WHO case definition for pandemic H1N1 [22]. Five
hundred and thirty-two cases (26%) tested positive for
influenza, 93% of which were 2009 H1N1. Similar to
Morocco, laboratory-confirmed cases of influenza during
this pandemic period were highest in children under the
age of 15. Overall, the 2009 H1N1 pandemic was report-
edly mild in Rwanda with 70% of cases presenting as ILI
and 30% as SARI. Approximately 12% of patients required327
j gREVIEW
328hospitalization, of which 69% received oseltamivir therapy,
and there were no deaths reported [22,27]. Chronic res-
piratory problems followed by cardiac disease were the
most common comorbid conditions associated with
influenza infection in this population [22]. Although
influenza was detected year-round in Rwanda, peaks of
disease were noted between February/March and October/
November, coinciding with the rainy seasons [27].
Kenya. In 2006, with support from the Centers for Dis-
ease Control and Prevention-Kenya, a national sentinel
surveillance system was established. Between July 1, 2007,
and June 30, 2013, almost 40,000 samples (0.09% of
Kenya’s population) were obtained from patients with ILI
and SARI [21]. Influenza was confirmed in 15% (1,030 of
6,712) of patients presenting with ILI and 11% (962 of
8,975) of those admitted with SARI in 2009 to 2010. Less
than 3% of SARI patients were of adult age, which is
perhaps due to surveillance bias or a disparity in the uti-
lization of healthcare resources between pediatric and adult
populations. Influenza transmission was detected each
month; however, peak disease activity was detected be-
tween July and November. Influenza vaccination was re-
ported in 1.6% of patients with ILI and 1.5% of patients
with SARI, highlighting the lack of access to potentially
life-saving public health interventions [21].
Democratic Republic of Congo. Beginning in 2007,
the Democratic Republic of Congo, home to approximately
67 million people, implemented sentinel surveillance for
influenza in the capital Kinshasa in response to the growing
threat of avian influenza [28]. In 2009, 1,311 samples were
collected from 1,048 patients presenting with ILI and 263
with SARI [17]. Influenza was confirmed in 208 (20%) of
the ILI cases and 41 (16%) of the SARI cases [17]. Similar
to other African countries, cases of SARI peaked in children
under the age of 14. Influenza activity appears to circulate
most commonly between January and March, but it peaked
in October during the 2009 H1N1 pandemic [17].
India, Southeast Asia, and Mongolia
India. In 2004, the Indian Council of Medical Research
established a systematic influenza surveillance network to
characterize the prevalence and burden of influenza in
India, the second most populous country in the world
(>1.2 billion people) [29,30]. Between May 2009 and
April 2010, 2,588 samples were tested for influenza and
699 (27%) were positive. The 2009 H1N1 virus accounted
for 80% (557 of 699) of influenza positive infections.
Influenza was detected in 35% of patients presenting with
ILI and 18% of those with SARI in India, which is
consistent with other lower-middle-income countries. The
2009 pandemic H1N1 was detected in all ages but peaked
in the age range 5 to 15 for those presenting with ILI.
Bangladesh. Bangladesh is a low-income country of 156
million people located east of India that experiencedapproximately 6,000 2009 H1N1-related deaths with an
estimated US $6.1 million in direct medical costs [13,31].
In collaboration with the government of Bangladesh, the
International Centre for Diarrhoeal Disease Research,
Bangladesh initiated a hospital-based influenza surveillance
network to better characterize the epidemiology of influ-
enza in Bangladesh. From 2009 to 2010, 2,377 samples at
the International Centre for Diarrhoeal Disease Research,
Bangladesh were collected, 391 (16%) of which were
positive for influenza [13]. Laboratory-confirmed influenza
was detected in 17% and 16% of patients presenting with
ILI and SARI, respectively. Only 1% of 495 SARI patients
over the age of 5 had underlying pulmonary comorbidities
compared with 3% of patients presenting with ILI [13].
Influenza infection was detected each month between May
2008 and September 2010, which is consistent with other
tropical countries. The limited access to health care and
vaccines in addition to a lack of antiviral drugs and
pervasive malnutrition were reported as likely contributors
to the increased mortality associated with influenza in
Bangladesh.
Bhutan. Bhutan, located just north of Bangladesh and
east of India, has a population of approximately 650,000
people and is considered a lower-middle-income country
by the World Bank. In collaboration with the Department
of Virology, Armed Force Research Institute for Medical
Sciences, based in Bangkok, Thailand, Bhutan launched an
influenza surveillance system in 2008. Initially, diagnostics
were performed in Thailand, as polymerase chain reac-
tionebased domestic influenza diagnostics were not
available until April 2010 [14]. Between June 2009 and
August 2010, 2,149 samples were collected, 711 (33%) of
which were positive for influenza. Of these, 487 (69%)
were found to be the 2009 pandemic H1N1 virus. As in
other low-income to lower-middle-income countries, the
most common age group infected with the 2009 H1N1
virus was 6- to 20 years (57%) with very few above the age
of 50 (<2%). Approximately 22 deaths were attributed to
influenza and/or pneumonia during the pandemic; how-
ever, none of these had samples obtained for laboratory
confirmation, further suggesting that the true burden of
influenza in under-resourced areas is unknown due to a
lack of standardized diagnostic testing.
Lao People’s Democratic Republic. Influenza-like
illness accounts for a significant proportion (50,390 of
509,313 or 10%) of all outpatient and emergency room
visits in Lao People’s Democratic Republic (PDR) from
2008 to 2010 [32]. Lao PDR is a lower-middle-income
country of 6.7 million people located in between
Thailand and Vietnam [33]. The Lao PDR national influ-
enza surveillance network was established in response to
emerging strains of influenza, including the H5N1 avian
strain and the 2009 H1N1 pandemic virus. Between 2008
and 2010, 523 cases (22%) of influenza were confirmed in
2,338 patients presenting with ILI. Influenza activity wasGLOBAL HEART, VOL. 9, NO. 3, 2014
September 2014: 325-336
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highest in children between the ages of 5 and 17 (33%)
followed by those 18 to 64 (28%). Strangely, influenza was
not detected in the 19 individuals older than 65 years of
age that were tested. Although Lao PDR crosses both
tropical and semitropical zones, influenza was detected
year-round typically and displayed peak activity between
August and November. Similar to most under-resourced
areas, seasonal and pandemic influenza vaccines are not
routinely available.
Philippines. The Philippines is an archipelago that is home
to over 98 million people and located north east of Malaysia
[34]. Since 2004, the Research Institute for Tropical Medi-
cine has established the National Influenza Center in the
Philippines, which consists of 2 sentinel sites in 12 of the 17
administrative regions. Of the 4,178 respiratory samples
collected from patients with ILI between January 2009 and
December 2010, 1,068 (26%) were positive for influenza,
48% of which were pandemic H1N1 [35]. Although the
seasonal strains of H1N1 and H3N2 more commonly
occurred in children under 5, the 2009 pandemic H1N1
predominantly infected individuals between the ages of 5
and 14. Between April 2009 and December 2011, 1,438
patients were admitted with SARI and 152 (11%) were
confirmed to have been infected with influenza. Similar to
other tropical countries, influenza was detected year-round
but appeared to peak from February to March and June to
September, coinciding with the rainy season.
Mongolia. The increased burden of influenza in resource-
limited areas is not geographically isolated to Africa, India,
or Southeast Asia. Although the first case of 2009 H1N1
pandemic influenza did not occur in Mongolia until
October 2009, a community-based serological study in the
Selenghe province suggests that once introduced, this virus
infected approximately 30% of the Mongolian population
during the first wave of the pandemic. The low population
density of Mongolia, in comparison to more developed or
urban nations, may explain the late appearance of this global
pathogen. More than one-half of the influenza infections
during this period occurred in individuals under 20 years of
age [36]. Although influenza is often a vaccine-preventable
illness, 93.9% of patients in this study did not receive an
influenza seasonal vaccine in the previous year. Unfortu-
nately, the 2009 H1N1 pandemic vaccine was not available
prior to January 2010, highlighting the limited access to
public health preventative strategies.
2009 PANDEMIC H1N1 MORTALITY
Influenza infection results in a substantial burden of illness
in resource-limited settings and is the etiology of 5% to
27% of all cases of SARI (Table 1). Mortality attributable to
influenza in these settings is difficult to determine as case
fatality rates in many of these countries are not regularly
reported. The lack of epidemiologic data surrounding
influenza-associated mortality in low-income countries is
highlighted by the fact that although Africa and SoutheastGLOBAL HEART, VOL. 9, NO. 3, 2014
September 2014: 325-336Asia account for 38% of the world’s population, only 12%
of the 2009 H1N1 deaths were reported from these re-
gions. Limited studies from low-income and low-middle-
income countries, such as those from India and Kenya,
demonstrate markedly elevated influenza-related mortality
rates in hospitalized patients ranging from 4% to 68%
(Table 2) [37e45]. Additionally, a recent meta-analysis of
the global burden of severe influenza in pediatric pop-
ulations reported that 99% of SARI cases in children
younger than 5 occur in low-income and middle-income
countries, 13% of which are due to influenza [46,47].
Modeling studies have estimated a disproportionate
burden of influenza in resource-limited settings. Using data
derived from symptomatic attack rates and case fatality rates
modified by a respiratory disease-related mortality multi-
plier, Dawood et al. [48] found that an estimated 201,200
(105,700 to 395,600) respiratory-related deaths associated
with 2009 H1N1 influenza occurred globally. This is more
than 15 times the reported number of laboratory deaths
from the 2009 H1N1 provided toWHO. Furthermore, 51%
of these deaths were estimated to have occurred in Africa
and Southeast Asia with an estimated 2.4-fold increase in
mortality in Africa and a 1.4-fold increase in Southeast Asia
compared with resource-rich countries; the true burden of
global influenza appears to reside in the most impoverished
and under-resourced nations [10,48].
These estimates were supported by the GLaMOR
(Global Pandemic Mortality) study, which used global and
regional estimates of pandemic H1N1 influenza deaths to
also highlight the disproportionate burden of influenza
morbidity and mortality in resource-limited settings. The
GLaMOR study, however, found differences in the regional
distribution of influenza-related mortality compared with
the aforementioned modeling study. Whereas the highest
mortality rates were estimated to occur in the Americas by
the GLaMOR study, Dawood et al. [48] projected the greatest
mortality in Africa, India, and Southeast Asia. Importantly,
neither study had reliable influenza-related mortality data
from Africa. In the case of the GLaMOR study, data was
derived from South Africa, an upper-middle-income country
that is vastly different from many other African countries in
terms of access to and quality of health care [49]. In contrast,
Dawood et al. [48] based their conclusions of increased
influenza-related mortality in Africa, India, and Southeast
Asia on increased respiratory-related mortality multipliers
proportional to case fatality rates from all respiratory-related
illness in these areas. Though this variance in regional
burden of disease underscores the deficient epidemiology, it
supports the growing understanding of the disproportionate
burden of influenza-associated morbidity and mortality in
resource-constrained environments.SPECIFIC RISK FACTORS FOR SEVERE INFLUENZA IN
RESOURCE-LIMITED SETTINGS
Since the start of the 2009 H1N1 pandemic, WHO and
member states have collected patient information in an329
TABLE 2. Mortality of hospitalized patients with influenza in low and lower-middle-income countries during the first year of the 2009
H1N1 pandemic
Country (Region) Income Level Date of Surveillance Hospitalized, n Case Fatality Rate, %
India (South) Lower middle May 2009eApril 2010 50 68
India Lower middle May 2009eApril 2010 54 55
India (Jodhpur Rajasthan) Lower middle 2009e2010 221 36
India (Kerala) Lower middle June 2009eDecember 2011 88 7
India (Saurashtra) Lower middle September 2009eFebruary 2010 274 25
India Lower middle August 2009eApril 2010 20 25
India (Andhra Pradesh) Lower middle 2009e2010 1,480 7
India (Western) Lower middle August 2009eFebruary 2010 63 22
Kenya Low June 2009eNovember 2009 88 4
Income level defined by World Bank definitions [23].
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influenza-infected patients to severe outcomes. Data from
70,000 patients hospitalized in 19 countries or administra-
tive regions with H1N1 influenza revealed that age,
cardiorespiratory disease, diabetes, and pregnancy are lead-
ing risk factors associated with severe disease [50]. Despite
the low level of infection seen in developed countries among
older adults, mortality was highest among those 50 to 64
years old and over 65 (relative risk [RR] ¼ 1.5 and 1.6,
respectively, compared with the general population) [50].
Only 1 country (Madagascar) was defined as low income;
the rest were among upper-middle-income and high-income
countries including Argentina, Australia, Canada, Chile,
China, France, Germany, Hong Kong SAR, Japan, Mexico,
the Netherlands, New Zealand, Singapore, South Africa,
Spain, Thailand, the United States, and the United
Kingdom. Recent studies have identified other risk factors
that may be playing a role in predisposing individuals from
low-income countries to more severe disease such as HIV
and malnutrition [51].
Cardiopulmonary comorbidities in particular have
been associated with poor outcomes especially in resource-
constrained environments. Patients with more severe
influenza including viral pneumonia were more likely to
have underlying cardiac disease. In Morocco, cardiovas-
cular comorbidities, including hypertension, were associ-
ated with an increased risk of death with an adjusted odds
ratio of 28.2 (95% confidence interval [CI]: 2 to 398.7;
p ¼ 0.013) [20,52,53]. Cardiac disease was also identified
as a leading risk factor for intensive care unit (ICU)
admission and death from influenza, with an RR of 8 for
severe disease in India [41,50].
Chronic infections such as tuberculosis and HIV, more
prevalent in low-income settings, are also associated with
severe disease. In South Africa, individuals with HIV
accounted for 20% of deaths due to 2009 H1N1 pandemic
influenza, which is notably higher than the 10% HIV
prevalence in the general population [54]. After controlling
for age, influenza infection of HIV-positive individuals was
noted to carry a 5-fold risk of SARI (RR ¼ 5.3; 95% CI: 4 to
6.9) compared with HIV-negative individuals [55e57]. Theincreased association between HIV infection and severe
influenza disease was greatest in the adults between the ages
of 25 and 44 [57]. HIV-infected individuals were also noted
to have increased rates of bacterial coinfection (58%)
compared with HIV-negative patients (44%), whereas only
10% to 30% of hospitalized patients in Argentina or the
United States were found to have bacterial coinfection
[58e60].
Malnutrition has long been suspected of predisposing
individuals to infection through its role in affecting the
immune response, but studies have provided conflicting
results. Both micro- and macronutrient deficiency have
been implicated in the development of immunodeficiency
in general and specifically in increasing the susceptibility to
influenza in animal models [61,62]. Additionally, malnu-
trition was associated with a poor response to influenza
vaccination in 1 study of elderly adults [63]. Yet, another
study among pediatric patients found no association be-
tween malnutrition and influenza [64]. Given the con-
flicting results, absence of sufficient data, and the fact that
95.9% of the 826 million undernourished people live in
resource-limited settings globally, the role of malnutrition
as a risk factor for severe influenza requires further inves-
tigation [65].
INFLUENZA-ASSOCIATED SEVERE DISEASE
Respiratory complications of influenza
Influenza infection typically results in a mild, self-limiting
upper respiratory tract infection with fever, cough, sore
throat, myalgia, rhinorrhea, conjunctivitis, and shortness of
breath. Severe influenza, defined by more severe organ
involvement or complications, is most commonly associated
with pulmonary complications including primary viral
pneumonia, secondary bacterial infection, and exacerbations
of underlying lung disease, and it is more often seen in older
adults or those with other high-risk conditions [66]. Addi-
tionally, influenza can progress to acute respiratory distress
syndrome (ARDS). Influenza infects respiratory epithelial
cells, including alveolar epithelial cells, resulting in flooding
of the alveolar lumen with protein-rich fluid, blood, andGLOBAL HEART, VOL. 9, NO. 3, 2014
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TABLE 3. Intensive care unit demographics, therapies, and outcomes in lower-middle, upper-middle, and high-income levels

























India Lower middle September 2009e
December 2009
106 64 (60) 85 (80) 18 (17) NR 62 (59) NR NR NR 5.5 14.4 (49)
Syria Lower middle 2009 80 32 (40) 58 (73)* 59 (74) NR 47 (80) NR NR NR 5 15.2 (51)
Mexico Upper middle 2009 58 31 (53) NR 48 (82.7) 34 (59) NR 4 (7) 1 (2) 0 9 20.1 20 (35)
Tunisia Upper middle November 2009e
January 2010
32 14 (44) 21 (34) 15 (46.9) 7 (22) NR NR NR NR 4 NR 9 (28)
South Korea High September 2009e
February 2010
245 111 (45) 136 (56) 162 (66.1) 88 (36) 106 (43) 21 (9) NR 12 (5) 7.7 19.1 80 (33)
Ireland High July 2009eJune
2010
77 37 (49) 47 (62) 50 (64.9) 39 (51) NR NR 17 (22) 4 (7) 5.9 NR 14 (18)




High 2009 722 376 (52) 336 (49) 64.60 NR NR NR NR 53/706 (8) NR NR 103 (14)
United
States
High 2009 154 23 (50) 48 (38) 58 NR NR NR NR NR NR NR 37 (24)
United
States
High MayeJune 2009 47 27 (57) 30 (64) NR NR NR NR NR NR 7 21 8 (17)
Upper-middle income countries are those with a per capita gross national income of >$4,125 but <$12,746 and high-income countries have per capita gross national income of
>$12,746 [23]. Income levels were determined by the World Bank [23]. ALI, acute lung injury; APACHE II, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory
distress syndrome; ECMO, extracorporeal membrane oxygenation; HFOV, high-frequency oscillatory ventilation; NR, not recorded SOFA, Sequential Organ Failure Assessment Score.
*ALI or ARDS.
gREVIEWjinflammatory cells, limiting oxygen gas exchange and
resulting in severe hypoxic respiratory failure. The patho-
genesis of influenza-induced ARDS has been reviewed pre-
viously [67]. The 2009 pandemicH1N1 virus led to ARDS in
30% to 80% of patients admitted to an ICU with increased
percentages associated with lower-income countries
(Table 3) [11,43,58,59,68e73].
Bacterial coinfection was first recognized as a major
complication of influenza during the 1918 epidemic that
resulted in the death of over 50 million individuals. Autopsy
reports suggest that close to 95% of severe illness and death
were associated with bacterial coinfection [74]. Infection with
the 2009 H1N1 pandemic strain was also associated with
secondary bacterial infection in approximately 20% to 40%of
ICU patients in most studies (Table 3) [58,59,68]. The
pathogenesis underlying influenza-bacterial coinfection is
likely multifactorial and involves changes to both the airway
defense, including decreased mechanical clearance of
invading bacteria through deficient ciliary movement, and
breakdown of the airway epithelium. Epithelial damage from
influenza infection is thought to be an important step in the
pathogenesis of secondary bacterial pneumonia by facilitating
bacterial adherence [75]. Additionally, influenza-associated
depletion of alveolar macrophages and alterations to the
innate immune response reduces the ability to fight invading
bacteria.
Cardiovascular complications of influenza
Although influenza is traditionally associated with respi-
ratory complications, cardiac sequelae are increasinglyGLOBAL HEART, VOL. 9, NO. 3, 2014
September 2014: 325-336recognized. In fact, an additional 83,300 (range 46,000 to
179,900) cardiovascular-related deaths worldwide have
been attributed to infection with the 2009 pandemic H1N1
virus, suggesting that the already substantial global mor-
tality burden of influenza is likely underestimated due to
unrecognized cardiopulmonary complications in influenza-
infected individuals worldwide [48].
The relationship between influenza and increased car-
diac morbidity and mortality was initially recognized in
epidemiologic studies demonstrating peaks of influenza ac-
tivity and cardiac-related deaths coinciding during winter
months [76]. Increases in cardiovascular deaths during
influenza epidemics further suggest an influenza-specific
causal association. The cardiovascular complications of
influenza range from asymptomatic electrocardiogram ab-
normalities to acute myocardial infarction. In a study of 30
adults with clinical evidence of influenza infection, 53% had
abnormal electrocardiograms on day 1 and 23% on day 11,
although serum troponin levels and echocardiographic
studies were unremarkable [77]. More severely, 15% of
influenza-infected army recruits had evidence ofmyocarditis
with increased levels of cardiac enzymes and echocardio-
graphic evidence of wall motion abnormalities [78].
More recently, studies have demonstrated myocardial
dysfunction during infectionwith the 2009H1N1 pandemic
influenza virus. An echocardiographic study of 28 patients
presenting with ILI to a hospital in Turkey revealed a global
myocardial performance index (sum of isovolumetric
contraction time and isovolumetric relaxation time divided
by ejection time; higher values correspond to increased331
j gREVIEW
332cardiac dysfunction) that was significantly higher in
2009 H1N1-infected patients as compared to patients with
non-influenza-related ILI [79]. Similarly, a Belgian study
using echocardiography to evaluate the incidence and he-
modynamic consequences of right and left ventricular
dysfunction in critically ill patients with 2009 H1N1 infec-
tion found that 72% of the 39 patients evaluated displayed
abnormal ventricular function; 46% (n ¼ 13) had isolated
left ventricular dysfunction, 39% (n¼ 11) had isolated right
ventricular abnormalities, and 14% (n¼ 4) had biventricular
dysfunction [80]. Interestingly, whereas left ventricular
function normalized after an initial decline, right ventricular
abnormalities tended to worsen over the course of illness.
Influenza infection has also been associated with acute
myocardial infarction [81,82]. The most compelling evi-
dence comes from influenza vaccination trials, which
demonstrate a 67% reduction in the risk of myocardial
infarction and a decrease in cardiovascular mortality from
8% in unvaccinated subjects to 2% among the vaccinated
(RR ¼ 0.25; 95% CI: 0.07 to 0.86; p ¼ 0.01) [83,84]. The
protective effect of influenza vaccines has been most pro-
nounced in older adults with a 19% reduced risk of hospi-
talization for heart disease, 23% reduction in
cerebrovascular accidents, and a 50% reduction in all-cause
mortality during influenza seasons [85,86]. Additionally, a
recent meta-analysis found that influenza vaccination was
associated with a lower risk of composite cardiovascular
events (RR ¼ .64; 95% CI: 0.48 to 0.86; p ¼ 0.003) [87].
Despite the current recommendation for patients with un-
derlying cardiovascular disease to receive influenza vacci-
nation coverage, coverage remains insufficient in the
resource-rich settings globally; in resource-limited environ-
ments, vaccines are very rarely available at all [88].2009 H1N1 ICU care and outcomes
Severe influenza requiring ICU admission is associated
with significant morbidity and mortality. In the United
States between April 2009 and April 2010, an estimated 61
million people were infected with the 2009 H1N1 virus,
resulting in over 250,000 hospitalizations and 12,500
deaths [72]. An estimated 23% to 34% of hospitalized
patients required admission to an ICU [72]. Even though
ICU admissions globally are associated with underlying
comorbidities, pregnancy, and/or a delay in antiviral ther-
apy, very little is known about critical care management
and outcomes in resource-limited settings. Recent studies
from India and Syria suggest that influenza-related critical
illness in low-income countries is associated with sub-
stantially greater mortality than in high-income countries
(Table 3).
A multicenter study from 3 ICU in South India re-
ported 106 (106 of 464; 22.8%) patients with 2009 H1N1
required admission to an ICU [43]. Of these, 18 (17%)
required invasive mechanical ventilation and 16 (15.1%)
needed dialysis. ICU mortality in South India was reported
as 49%. Despite lower severity of illness scores (APACHE II[Acute Physiology and Chronic Health Evaluation] or
SOFA [Sequential Organ Failure Assessment] scores where
higher scores are worse) among these patients, this ICU
case fatality rate is approximately 2-fold to 3-fold higher
than that reported in ICU in the United States, Canada,
New Zealand, or Australia (Table 3) [59].
Outcomes in ICU located in Syria were also worse than
in high-resource areas. In a retrospective review of 80 pa-
tients admitted to 4 ICU in Damascus, Syria, 58 (72.5%)
had acute lung injury or ARDS and 59 (73.7%) were me-
chanically ventilated [68]. APACHE II and SOFA scores
reported in Syria were similar to those in South India (15.2
and 5, respectively), and ICU mortality was similarly
elevated at 51% [43].
As suggested by the data in Syria and India, despite
markedly lower SOFA and APACHE II scores in resource-
limited countries, there is higher mortality in these settings
(Table 3) [43,68]. Furthermore, mortality rates from ICU
in upper-middle-income countries, including Mexico and
Tunisia, suggest that resource availability is linked to out-
comes in severe disease there as well. Mortality rates in
both countries were between those from lower-income and
higher-income countries (Table 3) [11,43,58,59,68e73].
Disparities in access to critical care resources may partly
explain some of the pandemic influenza mortality differ-
ences reported among high-income and low-income
countries. However, additional factors such as lack of
available trained staff, or even travel time to facilities, cost
of treatment for patients and families, and delays in pre-
sentation likely also contribute. For example, a recent
study showed that patients presenting to ICU in India
arrived on average 6 days after the onset of symptoms
versus patients in high-income countries who presented
3 to 4 days after [43].Disparity in access to treatment in resource-
constrained areas
The 2009 H1N1 influenza pandemic revealed the limita-
tions of current critical care capacity in all countries but no
more so than in resource-limited regions. Notable barriers
to treatment in resource-constrained locations included
lack of influenza diagnostics, vaccinations, antiviral medi-
cations, and even basic monitoring devices such as blood
pressure cuffs or pulse oximeters. Additionally, many
countries lacked basic supportive treatment such as oxygen
let alone more advanced critical care support, such as
mechanical ventilation or cardiopulmonary monitoring
[89,90].
Influenza vaccination remains the best defense against
seasonal influenza and may play a role in reducing the
severity of disease [91,92]. Unfortunately, the populations
in low-income countries, which bear a disproportionate
burden of disease, are least likely to have access to vacci-
nation. In a 2012 survey of 14 African countries, only 4
(29%) reported availability of seasonal influenza vaccines
[93]. However, within these countries, <2% of theGLOBAL HEART, VOL. 9, NO. 3, 2014
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population that had access were actually vaccinated. Re-
ports from Morocco, Mongolia, Kenya, and Lao PDR sug-
gest a similar deficiency in seasonal vaccine coverage with
only 2% to 6% of the population being vaccinated
[20,21,32,36]. Although data supporting vaccine efficacy
in low-income areas are limited, a recent prospective
controlled trial of maternal influenza immunization in
Bangladesh demonstrated not only reliable immunoge-
nicity of the inactivated vaccine in pregnant women but
also decreased infection in their newborn children
[94e96].
Antiviral neuraminidase inhibitors (NAI) are the
mainstay of pharmacological treatment for influenza; the
principal NAI used is oseltamivir. Access to antivirals,
however, has been identified as a major barrier to delivery
of effective care in resource-poor environments, due to
poor availability or high cost. Data from Argentina
demonstrated an increased severity of disease in patients
who received antiviral therapy >48 h from the onset of
symptoms compared with those treated earlier, including
increased risk of pneumonia (66.6% vs. 33.3%; p¼ 0.006),
ICU admission (68% vs. 32%; p ¼ 0.01), prolonged
hospitalization (11 vs. 7 days), need for oxygen (61.7%
vs. 38.2%; p ¼ 0.0001), and mechanical ventilation
(68.2% vs. 31.8%; p ¼ 0.002) [54]. In a survey of 40
countries about the availability of NAI, only 65% of
respondents (19 of 31) reported these drugs as being
available [93].
Early initiation of antiviral therapy correlates with
improved outcomes; however, there are significant dis-
parities in the dispensing of these drugs [97]. The increased
use of NAI in Japan correlated with decreased mortality
(0.15 per 100,000 people) in contrast to the conservative
distribution in Argentina, which experienced higher mor-
tality rates (1.73 per 100,000) [98]. Recently, a study
demonstrated a 1.6% reduction of H1N1 mortality with
each 10% increase in kilograms of oseltamivir distributed
[98]. Although the use of and timing of NAI in ICU found
in low-income countries was not regularly reported, it is
worth noting that only 29% to 43% of patients admitted to
ICU in high-income countries received NAI within 48 h of
symptom onset [71,72]. Improved education and aware-
ness of the efficacy and protocols for NAI may help. Early
initiation of antiviral therapy was reported to have
improved in Ukraine following a WHO mission there,
suggesting that real-time WHO guidance can affect clinical
management in the middle of a pandemic [54].
Supportive care including mechanical ventilation, car-
diopulmonary monitoring, and other invasive support is
essential in the management of critically ill influenza patients.
Mechanical ventilationwas requiredby approximately 40% to
80% of patients admitted to an ICU in both low-income and
high-income countries (Table 3) [11,43,58,59,68e73].
However, many resource-constrained environments lack ICU
capabilities. Moreover, even many upper-middle-income
countries have limited healthcare infrastructure, which can
be quickly overwhelmed and unable to meet the surgeGLOBAL HEART, VOL. 9, NO. 3, 2014
September 2014: 325-336demand of a pandemic; in these cases, such as in Mexico,
critically ill patients may be managed outside of ICU [11].
Similar strains on resources have been identified in Chile
where critical care beds and mechanical ventilators were
identified as limited resources [99]. Possible solutions may be
to develop experienced referral centers where outcomes of
patients with ARDS are improved; regionalizing critical care
services may improve outcomes in pandemic disease espe-
cially in areas where these resources are already limited [100].
A significant number of patients inhigh-incomecountries
receive salvage oxygenation therapies including prone posi-
tioning, extracorporeal membrane oxygenation (ECMO),
and/or neuromuscular blockade for severe influenza; these
therapies require experience and expertise that likely con-
tributes to the disparity in mortality between resource-rich
and resource-poor countries. Use of prone positioning may
be a viable option for severe lung injury and/or ARDS
resulting from influenza in resource-limited countries given
that expensive technology is not required. Prone positioning
has been shown to improve oxygenation and, more recently,
mortality in patients with severe ARDS [101]. It was reported
as used in 3% to 8%of critically ill patients in SouthKorea and
the Canada [59,71,101]. In Mexico, a more resource-
challenged country, prone position was implemented in
6.9% of patients admitted to ICU in Mexico (Table 3) [11].
Pronepositioning hasnot beenmentioned in any reports from
resource-limited countries, but should be considered as
inexpensive salvage therapy with appropriate education and
training for patients with refractory hypoxia. The use of
ECMO has increased in many ICU settings following
improved outcomes documented in the 2009 CESAR (Con-
ventional Ventilation or ECMO for Severe Adult Respiratory
Failure) trial. Approximately 4% to 7% of patients in high-
income countries were treated with the use of ECMO [75].
There are no reported cases of use in low-income countries.
Neuromuscular paralysis has been reported in Syria and India
where its use ismore frequent (58.5% to 79.7%) than in high-
income countries such as South Korea and Canada (28% to
43%); this may indicate both a need for and a lack of available
rescue oxygenation modalities in such settings (Table 3)
[43,59,68,71].
Precluding even advanced technology, some resource-
limited countries report a lack of even basic supportive
treatments including, for example, oxygen [69]. Oxygen is
considered an essential medicine byWHO and is onWHO’s
essential medicines list to guide resource-limited countries
on a basic formulary. Pulse oximeters and appropriate use of
oxygen therapy can reduce mortality in resource-limited
environments [102]. However, despite this priority, it has
been cited as “never available” in 11% of hospitals in low-
income and middle-income countries [90]. Similarly, in
hospitals that reported having oxygen, it was “sometimes
available” 33%of the time and only “always available” 21%of
the time [90]. Oxygen availability in Sub-Saharan Africa
represents a significant challenge; whereas 44% (99 of 231)
of health facilities in 12 Sub-Saharan countries surveyed in a
2007 to 2009 study reported access to oxygen, only 34% (75333
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334of 231) reported access to relevant, needed supplies such as
face masks or tubing [89].
SUMMARY
The first pandemic of the 21st century, 2009 H1N1,
exposed significant gaps in the current understanding of the
global burden of influenza. Lack of robust influenza
epidemiology in the world’s most populous and under-
resourced regions heralds a major deficiency in our un-
derstanding of the true burden of influenza. Though this
burden remains poorly characterized and underestimated,
there is growing recognition that resource-limited countries
bear a disproportionate burden of morbidity and mortality
from influenza globally. The difference in mortality between
high-resource and low-resource countries is likely attribut-
able in part to the increased prevalence of underlying high-
risk comorbidities such as untreated cardiopulmonary dis-
ease, HIV, and malnutrition, as well as limited availability of
antivirals, vaccines, and or supportive care resources such
as oxygen, mechanical ventilators, and salvage technologies
such as ECMO. Influenza is a preventable and treatable
cause of severe respiratory illness but resources that exist in
high-income countries will need to reach patients in
resource-limited countries where the burden is highest.
Hopefully, improved epidemiology of influenza can help
further guide allocation of preventative and supportive in-
terventions such as vaccines, antiviral medications, and
improved basic health care in order to mitigate the impact
of influenza infection on these most vulnerable populations.
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